Home/Browse by collection/EAHP Statement 5: Patient Safety and Quality Assurance

EAHP Statement 5: Patient Safety and Quality Assurance

Showing results 21 - 30 of 100

Sorted by most recent

Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort
Sandra Rotea-Salvo, Alejandro Martínez-Pradeda, Carla Fernández-Oliveira, Victor Giménez-Arufe, Vanesa Balboa-Barreiro, Luis Margusino-Framiñán, Álvaro Mena-De-Cea, Pilar Vázquez-Rodríguez, Ángeles Castro-Iglesias, Soledad López-Calvo, Isabel Martín-Herranz, Enrique Míguez-Rey, Purificación Cid-Silva

14 October 2021